Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $4.79

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned an average recommendation of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $4.79.

A number of research firms have recently weighed in on MRNS. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. HC Wainwright reiterated a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Finally, Royal Bank of Canada dropped their price target on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the second quarter worth about $28,000. SG Americas Securities LLC bought a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $34,000. AQR Capital Management LLC raised its holdings in Marinus Pharmaceuticals by 70.3% during the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $64,000. Finally, Values First Advisors Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 501.8% in the second quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares during the period. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ:MRNS opened at $0.23 on Friday. The firm has a market cap of $12.69 million, a P/E ratio of -0.09 and a beta of 1.25. Marinus Pharmaceuticals has a 12 month low of $0.23 and a 12 month high of $11.26. The company’s 50-day moving average price is $0.54 and its two-hundred day moving average price is $1.12.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.